Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

Affiliation auteurs!!!! Error affiliation !!!!
TitreJust how accurate are the major risk stratification systems for early-stage endometrial cancer?
Type de publicationJournal Article
Year of Publication2015
AuteursBendifallah S., Canlorbe G., Collinet P., Arsene E., Huguet F., Coutant C., Hudry D., Graesslin O., Raimond E., Touboul C., Darai E., Ballester M.
JournalBRITISH JOURNAL OF CANCER
Volume112
Pagination793-801
Date PublishedMAR 3
Type of ArticleArticle
ISSN0007-0920
Mots-clésendometrial cancer, Lymph node, Prediction, Recurrence, stratification
Résumé

Background: To compare the accuracy of five major risk stratification systems (RSS) in classifying the risk of recurrence and nodal metastases in early-stage endometrial cancer (EC). Methods: Data of 553 patients with early-stage EC were abstracted from a prospective multicentre database between January 2001 and December 2012. The following RSS were identified in a PubMed literature search and included the Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC-1), the Gynecologic Oncology Group (GOG)-99, the Survival effect of paraaortic lymphadenectomy (SEPAL), the ESMO and the ESMO-modified classifications. The accuracy of each RSS was evaluated in terms of recurrence-free survival (RFS) and nodal metastases according to discrimination. Results: Overall, the ESMO -modified RSS provided the highest discrimination for both RFS and for nodal metastases with a concordance index (C-index) of 0.73 (95% CI, 0.70-0.76) and an area under the curve (AUC) of 0.80 (0.78-0.72), respectively. The other RSS performed as follows: the PORTEC1, GOG-99, SEPAL, ESMO classifications gave a C-index of 0.68 (0.66-0.70), 0.65 (0.63-0.67), 0.66 (0.63-0.69), 0.71 (0.68-0.74), respectively, for RFS and an AUC of 0.69 (0.66-0.72), 0.69 (0.67-0.71), 0.68 (0.66-0.70), 0.70 (0.68-0.72), respectively, for node metastases. Conclusions: None of the five major RSS showed high accuracy in stratifying the risk of recurrence or nodal metastases in patients with early-stage EC, although the ESMO-modified classification emerged as having the highest power of discrimination for both parameters. Therefore, there is a need to revisit existing RSS using additional tools such as biological markers to better stratify risk for these patients.

DOI10.1038/bjc.2015.35